These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17933730)

  • 1. Antiviral drugs in the treatment of AIDS: what is in the pipeline ?
    Stellbrink HJ
    Eur J Med Res; 2007 Oct; 12(9):483-95. PubMed ID: 17933730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The integrase of the human immunodeficiency virus as a novel target for the antiviral therapy of AIDS.
    Witvrouw M; Debyser Z
    Verh K Acad Geneeskd Belg; 2003; 65(5):325-34. PubMed ID: 14671848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiretroviral therapy. Update at the beginning of a new century].
    Jablonowski H
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():5-13. PubMed ID: 10863303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
    Kiser JJ
    Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The search for potent, small molecule NNRTIs: A review.
    Prajapati DG; Ramajayam R; Yadav MR; Giridhar R
    Bioorg Med Chem; 2009 Aug; 17(16):5744-62. PubMed ID: 19632850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New classes of HIV drugs on the horizon. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
    O'Brien WA
    AIDS Read; 2003 Mar; 13(3 Suppl):S4-8. PubMed ID: 12765159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
    Josephson F; Albert J; Flamholc L; Gisslén M; Karlström O; Lindgren SR; Navér L; Sandström E; Svedhem-Johansson V; Svennerholm B; Sönnerborg A
    Scand J Infect Dis; 2007; 39(6-7):486-507. PubMed ID: 17577810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
    Hughes CA; Robinson L; Tseng A; MacArthur RD
    Expert Opin Pharmacother; 2009 Oct; 10(15):2445-66. PubMed ID: 19678794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
    Sweeney ZK; Klumpp K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):458-70. PubMed ID: 18600563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.
    Borrás-Blasco J; Navarro-Ruiz A; Borrás C; Casterá E
    J Antimicrob Chemother; 2008 Nov; 62(5):879-88. PubMed ID: 18653488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics.
    Young SD
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):402-10. PubMed ID: 11727305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The history of antiretrovirals: key discoveries over the past 25 years.
    De Clercq E
    Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly approved integrase inhibitors for clinical treatment of AIDS.
    Gu WG
    Biomed Pharmacother; 2014 Oct; 68(8):917-21. PubMed ID: 25451165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment options for pediatric HIV infection.
    Day E; Buckberry K; Sharland MR; Chakraborty R
    Curr Opin Investig Drugs; 2008 Feb; 9(2):170-5. PubMed ID: 18246519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.